Research Grade Tebentafusp (DHC27706)

Catalog No.

DHC27706

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

scFv-TCR

Clonality

Monoclonal

Target

CD3E, gp100 peptide-HLA Complex, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, T-cell surface glycoprotein CD3 epsilon chain

Concentration

1.06 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P07766

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

9mM Citric acid monohydrate, 41mM Na2HPO4, 1% Mannitol, 5% Trehalose, 0.02% Tween 20, 2mM DTT, pH 6.5.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific fusion protein, CAS: 1874157-95-5

Clone ID

Tebentafusp

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma, PMID: 31336704

Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma, PMID: 32816891

Uveal melanoma, PMID: 32273508

Immunotherapies for the Treatment of Uveal Melanoma-History and Future, PMID: 31344957

Novel Approaches to the Systemic Management of Uveal Melanoma, PMID: 32725406

Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours, PMID: 31207478

TCR Bispecific Boosts Survival in Uveal Melanoma, PMID: 33839690

Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives, PMID: 34431316

Document Download

Research Grade Tebentafusp.pdf